C4 Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $377.71M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | $6.60M | $-0.18 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | $6.20M | $-0.20 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $11.00M | $-0.18 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $11.20M | $-0.44 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $6.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $7.20M | $-0.37 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | $15.40M | $-0.35 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Press releases
Announcements C4 Therapeutics filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Protein degraded. Disease targeted. Lives transformed. September 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Protein degraded. Disease targeted. Lives transformed. June 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Protein degraded. Disease targeted. Lives transformed. May 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Protein degraded. Disease targeted. Lives transformed. April 2026
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Protein degraded. Disease targeted. Lives transformed. October 2025
Other events · EX-99.1 to Form 8-K
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Updated Data From Phase 1 Trial of Cemsidomide in Multiple Myeloma & Next Steps International Myeloma Society (IMS) Annual Meeting September 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Protein degraded. Disease targeted. Lives transformed. August 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Protein degraded. Disease targeted. Lives transformed. May 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Protein degraded. Disease targeted. Lives transformed. January 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
December 2024 Protein degraded. Disease targeted. Lives transformed.
Other events · EX-99.3 to Form 8-K
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K/A
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
January 2024 Protein degraded. Disease targeted. Lives transformed.
Regulation FD disclosure · EX-99.1 to Form 8-K
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
CFT7455, IKZF1/3 Degrader, for the Potential Treatment of Relapsed Refractory Multiple Myeloma (R/R MM) December 12, 2023 Phase 1 Dose Escalation Data
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K